Effects of ondansetron in obsessive-compulsive and tic disorders

Brief description of study

We are looking to enroll patients with Obsessive Compulsive Disorder (OCD) or Tic/Tourette’s Disorder (TD). The purpose of this study is to investigate whether the drug ondansetron (brand name Zofran) reduces symptoms and changes brain function in people with OCD or TD. Ondansetron is FDA-approved for the treatment of nausea but has been shown to reduce symptoms in people with OCD and TD in small studies. It works by blocking the transmission of a chemical in the brain (and elsewhere in the body) called serotonin, but it is unknown how this is related to symptom reductions found in patients with OCD and TD. If you participate in this study, you will be asked to take 24 mg of ondansetron, or placebo (which is a drug with no effect, like a sugar pill), every day for 4 weeks. You will also be asked to have brain scans using fMRI, which is a technology that non-invasively measures brain activity, both before and after the 4 week trial.

Clinical Study Identifier: s17-01608
ClinicalTrials.gov Identifier: NCT03239210
Principal Investigator: Emily R. Stern.
Other Investigator: Dan Iosifescu.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.